Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Alviar Restrepo

Cardiovascular Disease Gainesville, FL Medical Doctor

NPI 1598069783 CMS profile 2775170

1600 Sw Archer Rd, Gainesville, FL 32610

Open in the dashboard

General payments

$104,130

105 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$86,751 paid to institutions, not to them · program years 2020–2024

Through program year 2025, Carlos Alviar Restrepo of Gainesville, FL is reported in the CMS Open Payments database as having received $104,130 across 105 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $86,751 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,397 15
2024 General $11,471 14
2023 General $9,763 12
2022 General $21,324 13
2021 General $11,179 8
2020 General $13,647 10
2019 General $21,349 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Alviar Restrepo
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Carlos Alviar Restrepo were reported at $15,397. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Carlos Alviar Restrepo Cardiovascular Disease median Middle half National median
2019 $21,349 $450 $127–$1,392 $163
2020 $13,647 $242 $77–$751 $114
2021 $11,179 $335 $101–$1,037 $132
2022 $21,324 $395 $121–$1,211 $149
2023 $9,763 $443 $136–$1,283 $160
2024 $11,471 $450 $136–$1,323 $164
2025 $15,397 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $63,399 36 payments
  2. ZOLL Circulation Inc $28,798 32 payments
  3. Abiomed $6,442 13 payments
  4. ZOLL Medical Corporation $2,931 6 payments
  5. Boston Scientific Corporation $1,316 2 payments
  6. Inari Medical, Inc. $483 3 payments
  7. Maquet Cardiovascular U.S. Sales, L.L.C. $323 6 payments
  8. Medtronic, Inc. $217 3 payments
  9. Teleflex LLC $138 1 payment
  10. Ethicon US, LLC $39 1 payment
  11. Other $44 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $64,980 31 payments
  2. Consulting Fee $28,500 14 payments
  3. Travel and Lodging $5,044 24 payments
  4. Food and Beverage $2,384 34 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 1 payment
  6. Grant $1,222 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $63,399 36 payments
  2. Catheter Temperature Management $26,798 31 payments
  3. Temperature Management System Temperature Management $26,798 31 payments
  4. Temperature Management System Start-Up Kit Temperature Management $26,798 31 payments
  5. Temperature Management System Start-Up Kit Temperature Management $2,000 1 payment
  6. Catheter Temperature Management $2,000 1 payment
  7. Temperature Management System Temperature Management $2,000 1 payment
  8. Defibrillator $1,980 1 payment
  9. General Tachy $1,222 1 payment
  10. CT THROMBECTOMY SYSTEM KIT $483 3 payments
  11. Other $1,593 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Internal Medicine: 777

Drug cost

$266

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 12 $266

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record